CMPS
COMPASS Pathways Plc - American
$9.91
+5.54%
2026-05-08
About COMPASS Pathways Plc - American
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Key Fundamentals
Forward P/E
-7.90
EPS (TTM)
$-3.08
ROE
-565.3%
Profit Margin
0.0%
Debt/Equity
93.60
Price/Book
18.35
Beta
2.40
Market Cap
$1.27B
Avg Volume (10D)
4.1M
Recent Breakout Signals
No recent breakout signals detected for CMPS.
Recent Price Range (60 Days)
60D High
$10.21
60D Low
$4.88
Avg Volume
4.4M
Latest Close
$9.91
Get breakout alerts for CMPS
Sign up for Breakout Scanner to receive daily notifications when CMPS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
COMPASS Pathways Plc - American (CMPS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CMPS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CMPS operates in the Healthcare sector within the Medical Care Facilities industry. Data is provided for informational purposes only and does not constitute financial advice.